Assessment of semen parameters and Anti-müllerian hormone level in patients with chronic kidney disease on hemodialysis: a case control study

Background and objective: Chronic kidney disease (CKD) is a common health problem which is accompanied by considerable morbidity and mortality. Anti-müllerian hormone (AMH) is one of the hormones that are affected by CKD. The objective was to assess semen parameters and AMH level in CKD patients on hemodialysis.

Material and methods: This study was a case control study of 20 patients with stage 4 and 5 CKD on hemodialysis, attending Nephrology Outpatient Clinic and Renal Dialysis Unit of Suez Canal University hospital and 20 healthy fertile controls. Full history, clinical examination, kidney function tests and semen analysis were performed. AMH level in serum and seminal plasma was measured using ELISA.

Results: The mean AMH level in serum of case group was 3.35 ± 2.43 ng/mL versus 4.13 ± 3.17 ng/mL in the controls respectively (p > 0.05) while mean AMH level in semen of the case group was 2.13 ± 2.64 ng/mL compared to 9.37 ± 3.79 ng/mL in controls respectively (p < 0.05). There was a positive correlation between AMH in seminal plasma and sperm count, total sperm motility, progressive sperm motility and sperm viability, while the AMH level in serum was insignificantly related.

Conclusion: Semen parameters in CKD patients on hemodialysis were significantly poorer than normal controls AMH in seminal plasma was significantly decreased in CKD patients (stage 4–5 on hemodialysis) and significantly correlated with the semen parameters.

CKD; Serum AMH; Seminal AMH; Semen parameters

[1] Levin A, Stevens PE, Bilous RW, Coresh J, De Francisco ALM, De Jong PE, et al. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney International Supplements. 2013; 3: 1–150.

[2] Webster AC, Nagler EV, Morton RL, Masson P. Chronic Kidney Disease. Lancet. 2017; 389: 1238–1252.

[3] Eckersten D, Giwercman A, Bruun L, Christensson A. Anti-Müllerian hormone, a Sertoli cell-derived marker, is decreased in plasma of male patients in all stages of chronic kidney disease. Andrology. 2016; 3: 1160–1164.

[4] Palmer BF, Clegg DJ. Gonadal dysfunction in chronic kidney disease. Reviews in Endocrine & Metabolic Disorders. 2017; 18: 117–130.

[5] Lundy SD, Vij SC. Male infertility in renal failure and transplantation. Translational Andrology and Urology. 2020; 8: 173–181.

[6] Silva GP, Grangeiro VPX, Carneiro FP. Grangeiro, Seminal Ferritin And Seminal Parameters In Patients Undergoing Chronic Hemodialy-sis. International Archives of Medicine. 2017; 10.

[7] Xu HM, Li HG, Xu L, Zhang J, Chen W, Shi Q. The decline of fertility in male uremic patients is correlated with low expression of the cystic fibrosis transmembrane conductance regulator protein (CFTR) in human sperm. Human Reproduction. 2012; 27: 340–348.

[8] McLennan IS, Pankhurst MW. Anti-Müllerian hormone is a gonadal cytokine with two circulating forms and cryptic actions. Journal of Endocrinology. 2015; 226: R45–R57.

[9] MacLaughlin DT, Donahoe PK. Sex determination and differentiation. New England Journal of Medicine. 2004; 350: 367–378.

[10] Sriraman V, Niu E, Matias JR, Donahoe PK, MacLaughlin DT, Hardy MP, et al. Müllerian inhibiting substance inhibits testosterone synthesis in adult rats. Journal of Andrology. 2002; 22: 750–758.

[11] Eckersten D, Giwercman A, Christensson A. Male patients with terminal renal failure exhibit low serum levels of antimüllerian hormone. Asian Journal of Andrology. 2016; 17: 149–153.

[12] Xu H, Zhang M, Zhang H, Alpadi K, Wang L, Li R, et al. Clinical Applications of Serum Anti-Müllerian Hormone Measurements in both Males and Females: an Update. Innovation. 2021; 2: 100091.

[13] Levey AS, de Jong PE, Coresh J, El Nahas M, Astor BC, Matsushita K, et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney International. 2011; 80: 17–28.

[14] Tocci A, Lucchini C. Who reference values for human semen. Human Reproduction Update. 2010; 16: 559.

[15] Lehtihet M, Hylander B. Semen quality in men with chronic kidney disease and its correlation with chronic kidney disease stages. Andrologia. 2016; 47: 1103–1108.

[16] Holley JL, Schmidt RJ. Changes in fertility and hormone replacement therapy in kidney disease. Advances in Chronic Kidney Disease. 2013; 20: 240–245.

[17] Josso N, Rey R, Picard J. Testicular Anti-Müllerian hormone: clinical applications in DSD. Seminars in Reproductive Medicine. 2013; 30: 364–373.

[18] Sinisi AA, Esposito D, Maione L, Quinto MC, Visconti D, De Bellis A, et al. Seminal Anti-Müllerian hormone level is a marker of spermatogenic response during long-term gonadotropin therapy in male hypogonadotropic hypogonadism. Human Reproduction. 2008; 23: 1029–1034.

[19] Trbovich AM, Sluss PM, Laurich VM, O’Neill FH, MacLaughlin DT, Donahoe PK, et al. Müllerian Inhibiting Substance lowers testosterone in luteinizing hormone-stimulated rodents. Proceedings of the National Academy of Sciences of the United States of America. 2001; 98: 3393–3397.

[20] Prem AR, Punekar SV, Kalpana M, Kelkar AR, Acharya VN. Male reproductive function in uraemia: efficacy of haemodialysis and renal transplantation. British Journal of Urology. 1996; 78: 635–638.

[21] Eckersten D, Tsatsanis C, Giwercman A, Bruun L, Pihlsgård M, Christensson A. MicroRNA-155 and Anti-Müllerian Hormone: New Potential Markers of Subfertility in Men with Chronic Kidney Disease. Nephron Extra. 2019; 7: 33–41.

[22] Aksglaede L, Olesen IA, Carlsen E, Petersen JH, Juul A, Jørgensen N. Serum concentration of Anti-Müllerian hormone is not associated with semen quality. Andrology. 2018; 6: 286–292.

[23] Andersen JM, Herning H, Witczak O, Haugen TB. Anti-Müllerian hormone in seminal plasma and serum: association with sperm count and sperm motility. Human Reproduction. 2016; 31: 1662–1667.

[24] Kucera R, Ulcova-Gallova Z, Windrichova J, Losan P, Topolcan O. Anti-Müllerian hormone in serum and seminal plasma in comparison with other male fertility parameters. Systems Biology in Reproductive Medicine. 2017; 62: 223–226.

[25] Al-Qahtani A, Muttukrishna S, Appasamy M, Johns J, Cranfield M, Visser JA, et al. Development of a sensitive enzyme immunoassay for anti‐Müllerian hormone and the evaluation of potential clinical applications in males and females. Clinical Endocrinology. 2005; 63: 267–273.